Can-Fite BioPharma (CANF) Non Operating Income (2017 - 2023)
Can-Fite BioPharma's (CANF) quarterly Non Operating Income came in at $182000.0 in Q4 2023, down 74.07% YoY from $702000.0 in Q4 2022, and up 76.7% on a QoQ basis from $103000.0 in Q3 2023.
Can-Fite BioPharma (CANF) Non Operating Income (2017 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 7 years of Non Operating Income data on file, last reported at $182000.0 in Q4 2023.
- Quarterly Non Operating Income fell 74.07% year-over-year to $182000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $561000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $122000.0, down 51.2% from the prior year.
- Non Operating Income advanced to $182000.0 in Q4 2023, from $103000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $702000.0 in Q4 2022 to a low of -$409000.0 in Q2 2019.
- A 5-year average of $21350.0 and a median of -$63000.0 in 2020 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2019 — Non Operating Income plunged 189.5% — and 2022, when it jumped 880.0%.
- Tracing CANF's Non Operating Income over 5 years: stood at -$173000.0 in 2019, then jumped by 53.76% to -$80000.0 in 2020, then retreated by 12.5% to -$90000.0 in 2021, then jumped by 880.0% to $702000.0 in 2022, then tumbled by 74.07% to $182000.0 in 2023.
- The last three Non Operating Income figures came in at $182000.0 (Q4 2023), $103000.0 (Q3 2023), and $114000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 182,000.00 |
| Sep 30, 2023 | 103,000.00 |
| Jun 30, 2023 | 114,000.00 |
| Mar 31, 2023 | 162,000.00 |
| Dec 31, 2022 | 702,000.00 |
| Sep 30, 2022 | 44,000.00 |
| Jun 30, 2022 | -121,000.00 |
| Mar 31, 2022 | -64,000.00 |
| Dec 31, 2021 | -90,000.00 |
| Sep 30, 2021 | 110,000.00 |
| Jun 30, 2021 | -86,000.00 |
| Mar 31, 2021 | 293,000.00 |
| Dec 31, 2020 | -80,000.00 |
| Sep 30, 2020 | -96,000.00 |
| Jun 30, 2020 | -62,000.00 |
| Mar 31, 2020 | -66,000.00 |
| Dec 31, 2019 | -173,000.00 |
| Sep 30, 2019 | -157,000.00 |
| Jun 30, 2019 | -409,000.00 |
| Mar 31, 2019 | 121,000.00 |